Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026

Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026
Candel to present CAN-2409 data

Candel Therapeutics, Inc. announced that extended follow-up data from its phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer will be presented at the American Urological Association’s annual meeting, AUA2026, in Washington, D.C.

The data release is anticipated to provide further insight into the efficacy and durability of the CAN-2409 immunotherapy approach for patients with localized prostate cancer, potentially shaping future treatment strategies. The results will be shared with a broad audience of urology experts and researchers during the highly regarded urological conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.